These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7277091)

  • 1. Profiles of psychedelic drugs: 10. DOB.
    Shulgin A
    J Psychoactive Drugs; 1981; 13(1):99. PubMed ID: 7277091
    [No Abstract]   [Full Text] [Related]  

  • 2. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
    Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
    Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
    [No Abstract]   [Full Text] [Related]  

  • 3. Potent agonist activity of DOB at 5-HT2 receptors in guinea pig trachea.
    Heller WA; Baraban JM
    Eur J Pharmacol; 1987 Jun; 138(1):115-7. PubMed ID: 3622603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reevaluation of psychotomimetic amphetamine derivatives in humans.
    Cassels BK; Gómez-Jeria JS
    J Psychoactive Drugs; 1985; 17(2):129-30. PubMed ID: 4020537
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of 2,5-dimethoxy-4-methylamphetamine (DOM) on operant behavior: interactions with other neuroactive agents.
    Commissaris RL; Semeyn DR; Moore KE; Rech RH
    Commun Psychopharmacol; 1980; 4(5):393-404. PubMed ID: 6120791
    [No Abstract]   [Full Text] [Related]  

  • 6. [Studies on the identification of psychotropic substances. VI. Preparation and various analytical data of reference standards of some hallucinogens, 2,5-dimethoxy-4-methylamphetamine (STP), 2,5-dimethoxy-4-bromoamphetamine (DOB) and 2,5-dimethoxy-4-ethylamphetamine (DOET)].
    Shimamine M; Takahashi K; Nakahara Y
    Eisei Shikenjo Hokoku; 1989; (107):113-9. PubMed ID: 2636911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors.
    Ponzoni L; Braida D; Sala M
    Psychopharmacology (Berl); 2016 Aug; 233(15-16):3031-9. PubMed ID: 27318987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congeners of DOM: effect of distribution of the evaluation of pharmacologic data.
    Barfknecht CF; Caputo JF; Tobin MB; Dyer DC; Standirdge RT; Howell HG; Goodwin WR; Partyka RA; Gylys JA; Cavanagh RL
    NIDA Res Monogr; 1978; (22):16-26. PubMed ID: 101880
    [No Abstract]   [Full Text] [Related]  

  • 9. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse.
    Glennon RA; Titeler M; Lyon RA
    Pharmacol Biochem Behav; 1988 Jul; 30(3):597-601. PubMed ID: 3211969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
    Pierce PA; Peroutka SJ
    Psychopharmacology (Berl); 1989; 97(1):118-22. PubMed ID: 2540505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity.
    Rasmussen K; Glennon RA; Aghajanian GK
    Eur J Pharmacol; 1986 Dec; 132(1):79-82. PubMed ID: 3816969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.
    Sanders-Bush E; Breeding M
    Psychopharmacology (Berl); 1991; 105(3):340-6. PubMed ID: 1665919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The behavioral effects of 2,5-dimethoxy-4-alkyl amphetamines.
    Morin RD; Benington F; Mitchell SR; Beaton JM; Bradley RJ; Smythies JR
    Experientia; 1975 Jan; 31(1):93-5. PubMed ID: 234850
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of substituted-amphetamine hallucinogens using the cat limb flick model.
    Rusterholz DB; Spratt JL; Long JP; Barfknecht CF
    Commun Psychopharmacol; 1977; 1(6):589-92. PubMed ID: 608329
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents.
    Glennon RA; Rosecrans JA; Young R
    Med Res Rev; 1983; 3(3):289-340. PubMed ID: 6350763
    [No Abstract]   [Full Text] [Related]  

  • 16. Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG).
    Dimpfel W; Spüler M; Nichols DE
    Psychopharmacology (Berl); 1989; 98(3):297-303. PubMed ID: 2568652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs.
    Halberstadt AL; Chatha M; Stratford A; Grill M; Brandt SD
    Neuropharmacology; 2019 Jan; 144():368-376. PubMed ID: 30385253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indolealkylamine and phenalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substituents on behavioral activity.
    Glennon RA; Young R; Jacyno JM
    Biochem Pharmacol; 1983 Apr; 32(7):1267-73. PubMed ID: 6573879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LSD or DOB?
    Davis WM
    Am J Psychiatry; 1982 Dec; 139(12):1649. PubMed ID: 7149079
    [No Abstract]   [Full Text] [Related]  

  • 20. The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration.
    Owens MJ; Knight DL; Ritchie JC; Nemeroff CB
    J Pharmacol Exp Ther; 1991 Feb; 256(2):795-800. PubMed ID: 1847213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.